Royalty Pharma (RPRX) Receivables - Other (2020 - 2023)

Royalty Pharma (RPRX) has 4 years of Receivables - Other data on file, last reported at $14.2 million in Q4 2023.

• For the quarter ending Q4 2023, Receivables - Other fell 15.38% year-over-year to $14.2 million; the trailing twelve-month figure through Dec 2023 stood at $14.2 million (down 15.38% YoY), and the FY2023 full-year result was $14.2 million, down 15.38% from the prior year.
• Receivables - Other eased to $14.2 million in Q4 2023, from $16.4 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $59.7 million in Q3 2021 to a low of $14.2 million in Q4 2023.
• A 4-year average of $27.5 million and a median of $18.0 million in 2022 frame the typical range for Receivables - Other.
• Across the five-year window, Receivables - Other surged 84.29% in 2021 and plunged 73.66% in 2022, its largest moves.
• Tracing RPRX's Receivables - Other over 4 years: stood at $32.4 million in 2020, then surged by 84.29% to $59.7 million in 2021, then slumped by 71.79% to $16.8 million in 2022, then dropped by 15.38% to $14.2 million in 2023.
• Business Quant data shows RPRX's Receivables - Other at $14.2 million in Q4 2023, $16.4 million in Q3 2023, and $16.4 million in Q2 2023.